Table 3 Results of the statistical tests determining if there was a significant change in antibody level between the two time points (pre and post-treatment) and subsequently if any significant changes were related to praziquantel treatment
| Â | T-test | Multi-variate analysis | ||
|---|---|---|---|---|
Response | Z-value | P-value (2 tailed) | F-value | P-value |
WWH-IgG1 | -3.424 | 0.001 | 4.083 | 0.046 |
WWH-IgG3 | -1.206 | 0.228 | 0.054 | 0.816 |
MSP2 (CH150)-IgG1 | -0.927 | 0.354 | 0.012 | 0.914 |
MSP2 (CH150)-IgG3 | -1.658 | 0.098 | 0.068 | 0.974 |
MSP2 (Dd2)-IgG1 | -3.386 | 0.001 | 0.135 | 0.714 |
MSP2 (Dd2)-IgG3 | -0.895 | 0.371 | 0.849 | 0.359 |
MSP1 (DPK)-IgG1 | -0.738 | 0.460 | 0.094 | 0.760 |
MSP1 (DPK)-IgG3 | -1.885 | 0.059 | 0.676 | 0.413 |
MSP1 (MSP119)-IgG1 | -3.292 | 0.001 | 0.524 | 0.471 |
MSP1 (MSP119)-IgG3 | -3.927 | 0.000 | 0.069 | 0.793 |
Schizont-IgG1 | -2.342 | 0.019 | 0.018 | 0.894 |
Schizont-IgG3 | -0.970 | 0.332 | 0.227 | 0.635 |